Cited by 1,116Dementia and Cognitive Impairment ResearchMental Health and PsychiatryHistorical and Modern Theater Studies

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; none of the 24 sources its claims cite is checked for support yet.

Classifying neurocognitive disorders: the DSM-5 approach

Open access

Abstract

Neurocognitive disorders--including delirium, mild cognitive impairment and dementia--are characterized by decline from a previously attained level of cognitive functioning. These disorders have diverse clinical characteristics and aetiologies, with Alzheimer disease, cerebrovascular disease, Lewy body disease, frontotemporal degeneration, traumatic brain injury, infections, and alcohol abuse representing common causes. This diversity is reflected by the variety of approaches to classifying these disorders, with separate groups determining criteria for each disorder on the basis of aetiology. As a result, there is now an array of terms to describe cognitive syndromes, various definitions for the same syndrome, and often multiple criteria to determine a specific aetiology. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) provides a common framework for the diagnosis of neurocognitive disorders, first by describing the main cognitive syndromes, and then defining criteria to delineate specific aetiological subtypes of mild and major neurocognitive disorders. The DSM-5 approach builds on the expectation that clinicians and research groups will welcome a common language to deal with the neurocognitive disorders. As the use of these criteria becomes more widespread, a common international classification for these disorders could emerge for the first time, thus promoting efficient communication among clinicians and researchers.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrneurol.2014.181

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

26 Own interpretation · 16 Not checked yet · 14 No basis given · 6 Own method

Verify all 24 references — free account

Show all 13 claims

  • Probably not a substantial claim. 37
  • It may state two separate claims as one. 29
49 of 49
  • The authors state this as an assumption.

    Clinicians and research groups will welcome a common language for neurocognitive disorders.

    “The DSM-5 approach builds on the expectation that clinicians and research groups will welcome a common language to deal with the neurocognitive disorders.”
  • The paper relies on this without support.

    Mild and major neurocognitive disorders are categorical constructs imposed on an underlying continuum of cognitive impairment from normality to severe impairment.

    “Mild and major neurocognitive disorders are categorical diagnostic constructs imposed on an underlying continuum of cognitive impairment from normality to severe impairment, as seen in the clinic and the population.”
  • The paper relies on this without support.

    Mutations in APP or PSEN1/PSEN2 are causative for early-onset Alzheimer disease.

    “For example, the presence of mutations in the amyloid precursor protein gene (APP) or the presenilin genes (PSEN1 and PSEN2) is con sidered causative for AD with an early onset”
  • The paper relies on this without support.

    Neuroimaging is particularly important for determining vascular and frontotemporal degenerative aetiology.

    “Neuroimaging is particularly important in the neurocognitive disorders to determine vascular and frontotemporal degenerative aetiology.”
  • The paper relies on this without support.

    Subtyping neurocognitive disorders by cognitive profile is not very specific for aetiology in many settings.

    “However, the subtyping of neuro cognitive disorders by cognitive profile is not very specific for aetiology in many settings.”
  • The paper relies on this without support.

    Hypertension, diabetes, obesity, and metabolic syndrome are risk factors for vascular neurocognitive disorder but also increase Alzheimer disease risk and are consistent with other aetiologies.

    “For example, hypertension, diabetes, obesity and metabolic syndrome are risk factors for vascular neurocognitive disorder, but they also increase the risk for AD, and their presence is consistent with other aetiologies for neurocognitive disorder as well.”
  • The paper relies on this without support.

    Alzheimer disease is a neurodegenerative disorder with insidious onset and gradual progression of cognitive deficits.

    “AD is a neurodegenerative disorder with an insidious onset and gradual progression of cognitive deficits.”
  • The paper relies on this without support.

    In typical Alzheimer disease, decline in learning and memory is an early and predominant feature, and the decline is progressive without extended plateaus.

    “In a typical case, decline in learning and memory is an early and predominant feature, and the decline is progressive, without extended plateaus.”
  • The paper relies on this without support.

    The ε4 variant of apolipoprotein E is a risk factor for Alzheimer disease but not a diagnostic marker.

    “The presence of the ε4 variant of apolipoprotein E is a risk factor for AD but not a diagnostic marker.”
  • The paper relies on this without support.

    Alzheimer disease biomarkers include amyloid deposition on PET, reduced CSF amyloid-β42, elevated phosphorylated and total tau, hippocampal and temporoparietal atrophy on MRI, and temporoparietal hypometabolism on FDG PET.

    “Other markers include the demonstration of amyloid deposition in the brain using PET, reduced levels of amyloid-β 42 and elevated levels of phosphorylated tau and total tau in the cerebrospinal fluid, hippocampal and temporoparietal atrophy on MRI, and temporo parietal hypometabolism on 18 F-fluorodeoxyglucose PET.”
  • The paper relies on this without support.

    The concept of vascular neurocognitive disorder is broad and includes ischaemic and haemorrhagic lesions, as well as changes due to small vessel disease.

    “The concept of vascular neurocognitive disorder is broad and includes both ischaemic and haemorrhagic lesions, as well as changes due to small vessel disease.”
  • The paper relies on this without support.

    Structural MRI or CT has an important supportive role, and MRI can exclude clinically significant parenchymal injury due to vascular pathology.

    “Structural neuroimaging using MRI or CT has an important role as supportive evidence, and MRI can, in fact, be used to exclude the presence of clinically significant parenchymal injury due to vascular pathology.”
  • The paper relies on this without support.

    No biomarkers of vascular neurocognitive disorder other than neuroimaging have been established.

    “No biomarkers of vascular neurocognitive disorder, other than neuroimaging, have been established.”
  • The paper relies on this without support.

    Frontotemporal neurocognitive disorder comprises a number of syndromal variants with insidious onset and gradually progressive impairment of behaviour, personality, and/or language.

    “This group of neurodegenerative disorders comprises a number of syndromal variants with insidious onset and gradually progressive impairment of behaviour, personality and/or language.”
  • The paper relies on this without support.

    In familial frontotemporal cases, causative mutations have been identified in C9ORF72, MAPT, GRN, TDP-43, VCP, CHMP2B, and FUS.

    “In familial cases, a number of causative mutations have been identified in C9ORF72, and in genes coding for microtubule-associated protein tau (MAPT), granulins (GRN), TAR DNA-binding protein 43 (TDP-43), transitional endoplasmic reticulum ATPase (VCP), charged multivesicular body protein 2b (CHMP2B) and FUS protein (FUS).”
  • The paper relies on this without support.

    Frontotemporal neurocognitive disorder overlaps clinically and pathologically with progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease.

    “Frontotemporal neurocognitive disorder overlaps with progressive supranuclear palsy, corticobasal degeneration and motor neuron disease in terms of clinical and pathological profiles.”
  • The paper relies on this without support.

    Neurocognitive disorder with Lewy bodies presents with insidious onset and gradual progression, but early changes are in complex attention and executive function rather than learning and memory.

    “Like AD, this disorder presents with cognitive impairment of insidious onset and gradual progression, but the early changes are in complex attention and executive function rather than in learning and memory.”
  • The authors state this as an assumption.

    By convention, in neurocognitive disorder with Lewy bodies, major cognitive symptoms are observed at least 1 year before motor symptoms.

    “The presence of spontaneous parkinsonism is an important feature and, by convention, the major cognitive symptoms are observed at least 1 year before the motor symptoms.”
18 of 18

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. Sternberg, R. J. & Sternberg, K. Cognitive Psychology 6th edn (Cengage Learning, 2009).
  2. Lezak, M. D., Howieson, D. B. & Loring, D. W. Neuropsychological Assessment 4th edn (Oxford University Press, 2004).

Cited by

Sorted by citations

Items 301–400 of 1,000

Metadata

Authors
Sachdev, P. S., Blacker, D., Blazer, D. G., Ganguli, M., Jeste, D. V., Paulsen, J. S., & Petersen, R. C.
Affiliations
  • UNSW Sydney (AU)
  • Harvard University (US)
  • Duke University (US)
  • University of Pittsburgh (US)
  • University of California San Diego (US)
  • University of Iowa (US)
  • Mayo Clinic (US)
Corresponding author
Sachdev, Perminder S.
Venue
Nature Reviews Neurology
Published
2014-09-30
Volume
10
Issue
11
Pages
634-642
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W2048512926
Cited by
1,116
References
34
Citations by year
2026: 135 · 2025: 170 · 2024: 160 · 2023: 149 · 2022: 118 · 2021: 133 · 2020: 92 · 2019: 58 · 2018: 39 · 2017: 31 · 2016: 14 · 2015: 12 · 2014: 2
FWCI
2.72
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
  • eScholarship (California Digital Library) (submittedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
Funders
  • U.S. Department of Health and Human Services
  • National Institutes of Health
  • Medical Research Council
  • National Health and Medical Research Council (568969)
  • National Institute on Aging (P50AG005134, K07AG044395)
  • National Institute of Mental Health (MH099987, R01MH099987)
  • Sam and Rose Stein Institute for Research on Aging
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
  • Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
Keywords
neurocognitive disorders, DSM-5, diagnostic criteria, delirium, mild neurocognitive disorder, major neurocognitive disorder, mild cognitive impairment, dementia, Alzheimer's disease, cerebrovascular disease, Lewy body disease, frontotemporal lobar degeneration, traumatic brain injury
MeSH terms
Delirium, Dementia, Humans, Diagnostic and Statistical Manual of Mental Disorders, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review